Twitter LinkedIn
    Tuesday, July 5
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Investments»23andMe in Talks to Go Public Via Branson SPAC
    Investments

    23andMe in Talks to Go Public Via Branson SPAC

    January 31, 2021Updated:January 31, 20211 Min Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    DNA-testing company 23andMe is reportedly in talks to go public through a $4bn deal with Richard Branson’s VG Acquisition Corp.

    A deal may be announced next month for 23andMe, less than three years since being evaluated at $2.5bn.

    Bloomberg reports that the two sides are still far apart, but that talks are rapidly progressing.

    The deal would see 23andMe go public through Branson’s special purpose acquisition company (SPAC), which would be less risky than holding an initial public offering (IPO).

    The news sent shares in VG Acquisition soaring by as much as 18.4 per cent earlier today, before trading was halted.

    Currently its stock price is down slightly from the $13.65 it closed at yesterday.

    23andMe, which was founded in 2006, sells genetic testing kits directly to consumers and on Wednesday it launched a new Covid severity calculator.

    The company benefited from $869m of private funding since it opened, with GlaxoSmithKline one of its key backers.

    Source: City AM

    Image Source

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    2021 deals and transactions Investments PE Insider Private Equity
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    Clearlake Capital and Motive Partners complete acquisition of BETA+ from LSEG

    July 5, 2022

    Biosynth Carbosynth acquires KKR’s Pepscan

    July 5, 2022

    Triton to tap €5.2bn Fund V for OCU buyout

    July 5, 2022

    Private lenders are offering cheaper debt than Wall Street banks

    July 5, 2022

    Comments are closed.

    Other Articles

    Chinese Firm Buys Canada mRNA Vaccine Tech in $500 Million Deal

    September 15, 2021

    MasterClass raises USD225m in Series F funding round

    May 14, 2021

    Cloud firm Redis Labs valued at $2 billion as SoftBank and Tiger Global invest

    April 9, 2021

    HitecVision announces exclusive talks to buy Exxon’s UK assets

    January 22, 2021

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2022 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.

    Lost password?